Trials / Completed
CompletedNCT00203021
Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and Effectiveness
Open Label Study to Evaluate the Safety of Copaxone® and to Monitor the Neurologic Course of Disease in Multiple Sclerosis Patients Treated With Copaxone
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This open-label extension study will evaluate the long-term safety of glatiramer acetate and its effect on the neurologic course of participants with relapsing-remitting multiple sclerosis (RRMS). Participants have scheduled visits every 3 months to assess glatiramer acetate safety and their Multiple Sclerosis (MS) status.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Glatiramer acetate | Glatiramer acetate will be administered as per the dose and schedule specified in the respective arms. |
Timeline
- Start date
- 1994-03-26
- Primary completion
- 2018-02-28
- Completion
- 2018-02-28
- First posted
- 2005-09-20
- Last updated
- 2020-02-18
- Results posted
- 2019-07-18
Locations
11 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT00203021. Inclusion in this directory is not an endorsement.